Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
IgM, Human
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP024-05 |
-
|
Host |
Rabbit |
Klon |
SP108 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit Ig |
Verdünnung |
A synthetic peptide derived from near N-terminus of human IKAROS protein |
Lokalisation |
Nucleus |
IKAROS
|
Zytomed Systems GmbH |
SP108 |
1 ml |
Concentrate |
RUO |
509-4084 |
-
|
Host |
Rabbit |
Klon |
EP286 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pancreatic ductal adenocarcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human IMP3 |
Lokalisation |
Cytoplasm |
IMP3
|
Zeta Corporation |
EP286 |
1.0 ml |
Concentrate |
CE/IVD |
Z2284RL |
-
|
Host |
Rabbit |
Klon |
EP286 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pancreatic ductal adenocarcinoma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human IMP3 |
Lokalisation |
Cytoplasm |
IMP3
|
Zeta Corporation |
EP286 |
7 ml |
Ready-to-use |
CE/IVD |
Z2284RP |
-
|
Host |
Rabbit |
Klon |
EP286 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pancreatic ductal adenocarcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human IMP3 |
Lokalisation |
Cytoplasm |
IMP3
|
Zeta Corporation |
EP286 |
0.5 ml |
Concentrate |
CE/IVD |
Z2284RS |
-
|
Host |
Rabbit |
Klon |
EP286 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pancreatic ductal adenocarcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human IMP3 |
Lokalisation |
Cytoplasm |
IMP3
|
Zeta Corporation |
EP286 |
0.1 ml |
Concentrate |
CE/IVD |
Z2284RT |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex. |
Verdünnung |
1:10 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide corresponding to aa1-32 of human inhibin alpha subunit |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
R1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2115ML |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide corresponding to aa1-32 of human inhibin alpha subunit |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
R1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2115MP |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex. |
Verdünnung |
1:10 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide corresponding to aa1-32 of human inhibin alpha subunit |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
R1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2115MS |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex. |
Verdünnung |
1:10 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide corresponding to aa1-32 of human inhibin alpha subunit |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
R1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2115MT |
-
|
Host |
Mouse |
Klon |
ZM113 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex, testis, corpus luteum |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide (around aa 73-¬96) of α-subunit of human inhibin A protein |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
ZM113 |
1 ml |
Concentrate |
CE/IVD |
Z2413ML |
-
|
Host |
Mouse |
Klon |
ZM113 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex, testis, corpus luteum |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide (around aa 73-¬96) of α-subunit of human inhibin A protein |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
ZM113 |
7 ml |
Ready-to-use |
CE/IVD |
Z2413MP |
-
|
Host |
Mouse |
Klon |
ZM113 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex, testis, corpus luteum |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide (around aa 73-¬96) of α-subunit of human inhibin A protein |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
ZM113 |
0.5 ml |
Concentrate |
CE/IVD |
Z2413MS |
-
|
Host |
Mouse |
Klon |
ZM113 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortex, testis, corpus luteum |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide (around aa 73-¬96) of α-subunit of human inhibin A protein |
Lokalisation |
Cytoplasm |
Inhibin-α
|
Zeta Corporation |
ZM113 |
0.1 ml |
Concentrate |
CE/IVD |
Z2413MT |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Inhibin alpha
|
Diagnostic Biosystems |
R1 |
1 ml |
Concentrate |
CE/IVD |
MOB435 |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Inhibin alpha
|
Diagnostic Biosystems |
R1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB435-01 |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Inhibin alpha
|
Diagnostic Biosystems |
R1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB435-05 |
-
|
Host |
Mouse |
Klon |
R1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Inhibin alpha
|
Diagnostic Biosystems |
R1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM178 |
-
|
Host |
Mouse |
Klon |
25.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Mouse BAF47 aa 257-359 |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
25.0 |
1.0 ml |
Concentrate |
CE/IVD |
Z2177ML |
-
|
Host |
Mouse |
Klon |
25.0 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Mouse BAF47 aa 257-359 |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
25.0 |
7 ml |
Ready-to-use |
CE/IVD |
Z2177MP |
-
|
Host |
Mouse |
Klon |
25.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Mouse BAF47 aa 257-359 |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
25.0 |
0.5 ml |
Concentrate |
CE/IVD |
Z2177MS |
-
|
Host |
Mouse |
Klon |
25.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Mouse BAF47 aa 257-359 |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
25.0 |
0.1 ml |
Concentrate |
CE/IVD |
Z2177MT |
-
|
Host |
Rabbit |
Klon |
ZR282 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
HIER |
Positivkontrolle |
Epitheloid sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length human BAF47 protein |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
ZR282 |
1 ml |
Concentrate |
CE/IVD |
Z2597RL |
-
|
Host |
Rabbit |
Klon |
ZR282 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
HIER |
Positivkontrolle |
Epitheloid sarcoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Full-length human BAF47 protein |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
ZR282 |
7 ml |
Ready-to-use |
CE/IVD |
Z2597RP |
-
|
Host |
Rabbit |
Klon |
ZR282 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
HIER |
Positivkontrolle |
Epitheloid sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length human BAF47 protein |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
ZR282 |
0.5 ml |
Concentrate |
CE/IVD |
Z2597RS |
-
|
Host |
Rabbit |
Klon |
ZR282 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
HIER |
Positivkontrolle |
Epitheloid sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length human BAF47 protein |
Lokalisation |
Nucleus |
INI-1
|
Zeta Corporation |
ZR282 |
0.1 ml |
Concentrate |
CE/IVD |
Z2597RT |
-
|
Host |
Mouse |
Klon |
A8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Neuroendocrine tumor. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM |
Lokalisation |
Nucleus |
INSM1
|
Zeta Corporation |
A8 |
1 ml |
Concentrate |
CE/IVD |
Z2330ML |
-
|
Host |
Mouse |
Klon |
A8 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Neuroendocrine tumor. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM |
Lokalisation |
Nucleus |
INSM1
|
Zeta Corporation |
A8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2330MP |
-
|
Host |
Mouse |
Klon |
A8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Neuroendocrine tumor. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM |
Lokalisation |
Nucleus |
INSM1
|
Zeta Corporation |
A8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2330MS |
-
|
Host |
Mouse |
Klon |
A8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Neuroendocrine tumor. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM |
Lokalisation |
Nucleus |
INSM1
|
Zeta Corporation |
A8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2330MT |
-
|
Host |
Mouse |
Klon |
A-8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
neuroendocrine tumor |
Verdünnung |
1:50-1:200 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM1 |
Lokalisation |
Nuclear |
INSM1 (A-8)
|
Diagnostic Biosystems |
A-8 |
1 ml |
Concentrate |
CE/IVD |
MOB586 |
-
|
Host |
Mouse |
Klon |
A-8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
neuroendocrine tumor |
Verdünnung |
1:50-1:200 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM1 |
Lokalisation |
Nuclear |
INSM1 (A-8)
|
Diagnostic Biosystems |
A-8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB586-01 |
-
|
Host |
Mouse |
Klon |
A-8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
neuroendocrine tumor |
Verdünnung |
1:50-1:200 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM1 |
Lokalisation |
Nuclear |
INSM1 (A-8)
|
Diagnostic Biosystems |
A-8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB586-05 |
-
|
Host |
Mouse |
Klon |
A-8 |
Format |
ready- |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
neuroendocrine tumor |
Verdünnung |
--- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Amino acid 81-125 at the N-terminus of human INSM1 |
Lokalisation |
Nuclear |
INSM1 (A-8)
|
Diagnostic Biosystems |
A-8 |
6 ml |
ready- |
CE/IVD |
PDM586 |
-
|
Host |
Mouse |
Klon |
2D11 |
Format |
Purified |
Methode |
P, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native |
Insulin
|
Zytomed Systems GmbH |
2D11 |
200 µg |
Purified |
RUO |
609-0755 |
-
|
Host |
Mouse |
Klon |
K36ac10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Insulin
|
Diagnostic Biosystems |
K36ac10 |
1 ml |
Concentrate |
CE/IVD |
MOB234 |
-
|
Host |
Mouse |
Klon |
K36ac10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Insulin
|
Diagnostic Biosystems |
K36ac10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB234-01 |
-
|
Host |
Mouse |
Klon |
K36ac10 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Insulin
|
Diagnostic Biosystems |
K36ac10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB234-05 |
-
|
Host |
Mouse |
Klon |
ZM83 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ/ IgG1 /κ |
Verdünnung |
Recombinant INS protein |
Lokalisation |
Cytoplasm |
Insulin
|
Zeta Corporation |
ZM83 |
1.0 ml |
Concentrate |
CE/IVD |
Z2525ML |
-
|
Host |
Mouse |
Klon |
ZM83 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
- |
Isotyp |
IgG1 /κ/ IgG1 /κ |
Verdünnung |
Recombinant INS protein |
Lokalisation |
Cytoplasm |
Insulin
|
Zeta Corporation |
ZM83 |
7 ml |
Ready-to-use |
CE/IVD |
Z2525MP |
-
|
Host |
Mouse |
Klon |
ZM83 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ/ IgG1 /κ |
Verdünnung |
Recombinant INS protein |
Lokalisation |
Cytoplasm |
Insulin
|
Zeta Corporation |
ZM83 |
0.5 ml |
Concentrate |
CE/IVD |
Z2525MS |
-
|
Host |
Mouse |
Klon |
ZM83 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ/ IgG1 /κ |
Verdünnung |
Recombinant INS protein |
Lokalisation |
Cytoplasm |
Insulin
|
Zeta Corporation |
ZM83 |
0.1 ml |
Concentrate |
CE/IVD |
Z2525MT |
-
|
Host |
Mouse |
Klon |
5B6/6 |
Format |
Purified |
Methode |
F, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native |
Insulin (Proinsulin)
|
Zytomed Systems GmbH |
5B6/6 |
200 µg |
Purified |
RUO |
609-0761 |
-
|
Host |
Goat |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB |
Isotyp |
Goat IgG |
Verdünnung |
Recombinant mouse IGF-I |
Insulin-Like Growth Factor I (IGF1)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
609-0769 |
-
|
Host |
Mouse |
Klon |
M23 |
Format |
Purified |
Methode |
F |
Isotyp |
Mouse IgG1 |
Insulin-Like Growth Factor I (IGF1)
|
Zytomed Systems GmbH |
M23 |
100 µg |
Purified |
RUO |
609-0770 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant human IGF-I |
Insulin-Like Growth Factor I (IGF1)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
609-1047 |
-
|
Host |
Mouse |
Klon |
P1F6 |
Format |
Purified |
Methode |
F, IF, EL, FL, IP |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human UCLA P3 cells (lung carcinoma) |
Integrin alphaV, beta5
|
Zytomed Systems GmbH |
P1F6 |
100 µg |
Purified |
RUO |
609-0778 |
-
|
Host |
Mouse |
Klon |
DB-1 |
Format |
Purified |
Methode |
F, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Recombinant rat IFN gamma |
Interferon gamma (IFNg)
|
Zytomed Systems GmbH |
DB-1 |
100 µg |
Purified |
RUO |
609-0795 |
-
|
Host |
Mouse |
Klon |
49/20 |
Format |
Purified |
Methode |
WB, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human Interleukin-1 soluble receptor, type 1 expressed in insect cell line Sf |
Interleukin 1 Receptor Type I (IL-1R, CD121a)
|
Zytomed Systems GmbH |
49/20 |
100 µg |
Purified |
RUO |
609-0848 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant mouse IL-4 |
Interleukin 4 (IL-4)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
609-0951 |
-
|